Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery hosts UK Automated Synthesis Forum 2015

Sygnature Discovery hosted the UK Automated Synthesis Forum (UKASF) 2015 on November 11th/12th in Nottingham.

The forum aims to bring together best practice, and review new technologies to facilitate innovation in the small and large-scale chemical environment.

Over 85 delegates, from academia and industry, attended the two-day meeting and exhibition, which opened with a welcome from Sygnature Discovery’s CEO and Founder, Dr Simon Hirst.

Simon shared the developments at Sygnature since the company hosted the UKASF in 2012.

“A lot has changed,” he said. “We have grown from 70 to 134 staff, 115 of whom are scientists. We have built 15,500 compounds in libraries for IMI and opened a further 2 laboratories.”

Simon continued, “We have recently invested into Biophysics and DMPK, as well as investing over £4m in facilities and equipment.”

Plans for further expansion are already underway with two additional laboratories set to be opened in 2016. In 2017, the opening of the new, purpose built “Discovery Building” at BioCity, will become Sygnature’s new facility.

Sygnature Discovery has a clear ethos that better drug discovery research will lead to better medicines and improved patient outcomes.

Simon commented, “Better research needs bright, motivated and innovative scientists and the best tools we can lay our hands on.”

Dr Jason Tierney, chair of the UKASF organising committee, introduced the exhibitor flash presentations.

The UKASF was formed in 1996, during the combinational chemistry era within the pharmaceutical industry. The group was set up to discuss the issues encountered using automated equipment primarily for solid phase and array synthesis. Over the years, the meeting has evolved to include analytical equipment, new and emerging technologies including green chemistry.

The two-day meeting included flash presentations from the exhibitors, sessions on post reaction processing, closed loop optimization and, new synthesis and discovery paradigms.

Latest News

View All

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Paper on drug discovery equipment

500 – and counting!

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.